UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 177

Sortiert nach

Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events

Circulation (New York, N.Y.), 2006-05, Vol.113 (19), p.2278-2284

2006

Volltextzugriff (PDF)

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

The lancet oncology, 2018-05, Vol.19 (5), p.603-615

2018

Volltextzugriff (PDF)

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

The lancet oncology, 2018-10, Vol.19 (10), p.1315-1327

2018

Volltextzugriff (PDF)

Genome-Wide siRNA Screen for Modulators of Cell Death Induced by Proteasome Inhibitor Bortezomib

Cancer research (Chicago, Ill.), 2010-06, Vol.70 (11), p.4318-4326

2010

Volltextzugriff (PDF)

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma

European journal of cancer (1990), 2020-02, Vol.126, p.33-44

2020

Volltextzugriff (PDF)

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management

European journal of cancer (1990), 2019-09, Vol.119, p.97-106

2019

Volltextzugriff (PDF)

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

Clinical cancer research, 2016-02, Vol.22 (4), p.847-857

2016

Volltextzugriff (PDF)

A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma

Investigational new drugs, 2016-08, Vol.34 (4), p.439-449

2016

Volltextzugriff (PDF)

A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K -mutant Solid Tumors

Clinical cancer research, 2020-10, Vol.26 (19), p.5102-5112

2020

Volltextzugriff (PDF)

Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways

Molecular cancer therapeutics, 2014-06, Vol.13 (6), p.1625-1635

2014

Volltextzugriff (PDF)

PKC-theta-deficient mice are protected from Th1-dependent antigen-induced arthritis

Journal of Immunology, 2006-08, Vol.177 (3), p.1886-1893

2006

Volltextzugriff (PDF)

A Quantitative Framework and Strategies for Management and Evaluation of Metabolic Drug-Drug Interactions in Oncology Drug Development: New Molecular Entities as Object Drugs

Clinical pharmacokinetics, 2010-11, Vol.49 (11), p.703-727

2010

Volltextzugriff (PDF)

Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial

Leukemia & lymphoma, 2010-07, Vol.51 (7), p.1269-1277

2010

Volltextzugriff (PDF)

Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.10012-10012

2020

Volltextzugriff (PDF)

Response to Letter Regarding Article, “Platelet Expression Profiling and Clinical Validation of Myeloid-Related Protein-14 as a Novel Determinant of Cardiovascular Events”

Circulation (New York, N.Y.), 2007-02, Vol.115 (6)

2007

Volltextzugriff (PDF)

Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9507-9507

2021

Volltextzugriff (PDF)

A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.10022-10022

2020

Volltextzugriff (PDF)

Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600–mutant melanoma

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9512-9512

2019

Volltextzugriff (PDF)

A Flexible Method Using a Parametric Bootstrap for Reducing Bias in Adaptive Designs With Treatment Selection

Statistics in biopharmaceutical research, 2014-04, Vol.6 (2), p.163-174

2014

Volltextzugriff (PDF)

Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF -mutant melanoma

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9504-9504

2018

Volltextzugriff (PDF)

Adverse events of special interest in the phase 3 COLUMBUS study

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9567-9567

2018

Volltextzugriff (PDF)

A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAF V600E/K -mutant Solid Tumors

Clinical cancer research, 2020-10, Vol.26 (19), p.5102

2020

Volltextzugriff (PDF)

1 – 25 von 177

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(167)
Mit Volltextzugriff
(150)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(112)
Life Sciences & Biomedicine
(101)
Humans
(72)
Male
(46)
Biological And Medical Sciences
(45)
Female
(34)
Adult
(29)
Medical Sciences
(27)
Middle Aged
(27)
Animals
(21)
Aged
(20)
Neurosciences & Neurology
(20)
Fundamental And Applied Biological Sciences. Psychology
(19)
Neurosciences
(19)
Microbiology
(13)
Clinical Neurology
(12)
Oncology
(12)
Adolescent
(10)
Biochemistry & Molecular Biology
(10)
Biotechnology
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

Genome-Wide siRNA Screen for Modulators of Cell Death Induced by Proteasome Inhibitor Bortezomib

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma

A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K -mutant Solid Tumors

Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

PKC-theta-deficient mice are protected from Th1-dependent antigen-induced arthritis

A Quantitative Framework and Strategies for Management and Evaluation of Metabolic Drug-Drug Interactions in Oncology Drug Development: New Molecular Entities as Object Drugs

Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial

Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma

Response to Letter Regarding Article, “Platelet Expression Profiling and Clinical Validation of Myeloid-Related Protein-14 as a Novel Determinant of Cardiovascular Events”

Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma

A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2)

Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600–mutant melanoma

Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)

Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)

A Flexible Method Using a Parametric Bootstrap for Reducing Bias in Adaptive Designs With Treatment Selection

Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF -mutant melanoma

Adverse events of special interest in the phase 3 COLUMBUS study

A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAF V600E/K -mutant Solid Tumors

Suchergebnisse filtern